| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 6.3K | 10.6% |
| Total Income | 6.3K | 10.9% |
| Expenditure | 4.9K | 2.1% |
| PBT | 1.4K | 58.0% |
| Net Profit | 1.2K | 56.1% |
| OPM | 27.55% | 4.24pp |
| NPM | 19.24% | 5.57pp |
| EPS | 26.70 | 57.7% |
Lupin Ltd Reports Q1 FY2026 Results: Sales Up 11.8%, Net Debt at INR -12,386 Mn
05 Aug 2025 · 5 Aug 2025, 09:02 pm
Summary
Pharma major Lupin Limited reported its financial performance for the quarter ending June 30, 2025. The company's sales, EBITDA, PBT, and PAT all showed significant growth compared to the same period last year.
Key Highlights
- 1
Sales for Q1 FY2026 were INR 61,638 Mn, up 11.8% YoY
- 2
EBITDA for Q1 FY2026 was INR 18,063 Mn, up 38.0% YoY
- 3
PBT for Q1 FY2026 was INR 14,155 Mn, up 42.5% YoY
- 4
PAT for Q1 FY2026 was INR 12,215 Mn, up 51.6% YoY
- 5
Net Debt as on June 30, 2025, stands at INR -12,386 Mn
- 6
Lupin received approval for 2 ANDAs from the U.S. FDA in the quarter
Management Comments
Mr. Nilesh Gupta
We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments. As we begin the year, our sharpened focus on compliance, innovation, and technology positions us to further unlock sustainable growth
Informational and educational content only. Not investment advice.